1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Concord Medical Co., Ltd.

Concord Medical Co., Ltd.

6518.TWO
Concord Medical Co., Ltd.TW flagTaipei Exchange
32.60
TWD
+0.60
- -
1.09BMarket Cap
Concord Medical Co., Ltd.
6518.TWO
(Taipei Exchange)

Recent

price

32.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
8.41
13.51
16.32
20.79
24.26
25.88
28.12
30.55
32.39
29.51
26.68
25
26.7
- -
Revenue per Share
0.18
0.37
1.23
1.6
0.45
0.03
0.61
1.26
0.79
1.37
1.52
1.28
1.49
- -
Basic EPS, GAAP
-0.03
-21.91
-8.08
-1.03
-0.17
-0.57
1.85
2.44
-0.4
4.61
3.5
0.71
2.17
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.4
0.4
- -
0.4
0.4
0.4
0.5
1
1
- -
Dividend per Share
0.01
17.53
13.2
12.77
12.66
12.24
12.66
13.38
13.3
18.33
14.8
15.08
15.54
- -
Book Value per Share
0.01
21.77
17.74
16.34
16.69
16.74
17.49
18.59
19.36
25.39
21.29
20.35
20.84
- -
Tangible Book Value per Share
5,325
9
21
25
25
25
25
25
25
25
33
33
33
- -
Basic Weighted Avg Shares
44,779
128
349
520
607
647
703
764
810
739
889
833
890
964
Sales/Revenue/Turnover
10.27
8.58
10.2
10.99
3.65
1.86
3.36
5.04
3.46
4.82
7.21
6.59
6.95
7.55
Operating Margin (%)
9
27
62
63
62
72
79
106
103
97
76
79
86
85
Depreciation Expense
958
3
26
40
11
1
15
31
20
34
51
43
50
67
Net Income, GAAP
69.62
11.21
20.37
22.02
35.16
64.91
20.23
20.16
22.68
19.61
21.15
21.61
20.62
17.99
Effective Tax Rate (%)
2.14
2.7
7.53
7.67
1.86
0.1
2.18
4.11
2.44
4.65
5.7
5.13
5.57
6.99
Profit Margin (%)
-12
-78
-39
-96
-41
1
78
90
115
266
379
356
345
265
Working Capital
226
217
184
154
147
132
113
318
288
172
160
184
176
122
LT Debt
77
258
468
488
486
477
486
503
513
638
712
681
697
754
Total Equity
- -
2.04
3.89
5.03
1.58
0.49
2.56
4
2.49
3.33
5.68
4.73
5.4
6.4
Return on Invested Capital (%)
- -
2.24
5.54
6.2
2.14
0.34
3.28
6.27
3.57
5.65
7.6
6.28
7.24
9.39
Return on Capital (%)
- -
3.16
11.72
13.27
3.55
0.2
4.91
9.64
5.93
8.69
10.64
8.59
9.71
12.63
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.73%
8.42%
8.16%
Free Cash Flow
-142.9%
-213.42%
68.27%
Net Income, GAAP
235.66%
31.5%
35.9%
Sales/Revenue/Turnover
6.71%
4.09%
8.37%
Total Cash Common Dividend
- -
- -
10%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
833
2024
- -
- -
- -
- -
890
2025
- -
- -
- -
- -
964

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.28
2024
- -
- -
- -
- -
1.49
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -
Similar Companies
DENTSPLY SIRONA Inc. (XRAY)
HOYA Corporation (HOCPF)
Femasys Inc. (FEMY)
Wearable Health Solutions, Inc. (WHSI)
Maider Medical Industry Equipment Co. Ltd. (688310.SS)
HOYA Corporation (7741.T)
Business
Concord Medical Co., Ltd. (6518.TWO) operates as a medical equipment provider focused on radiotherapy and diagnostic imaging solutions in Taiwan. The company offers linear accelerators, CT scanners, MRI systems, positron emission tomography (PET)/CT scanners, brachytherapy equipment, and related maintenance and installation services; it also provides radiation therapy planning software and dosimetry products. Headquartered in Taipei, Taiwan, Concord Medical was founded in 1993 and primarily serves hospitals, clinics, and diagnostic centers across Taiwan with a network of sales, leasing, and after-sales support. In recent developments, the company expanded its product portfolio through a strategic partnership with a leading international radiotherapy equipment manufacturer in 2024, enhancing its access to advanced proton therapy systems. Additionally, Concord Medical completed a significant funding round in late 2024 to support the acquisition of a domestic imaging equipment distributor, bolstering its market share in northern Taiwan. These moves reflect ongoing efforts to diversify into precision oncology treatments and digital health integration amid growing demand for cancer care technologies.